Overview

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).
Phase:
PHASE3
Details
Lead Sponsor:
RenJi Hospital
Collaborator:
Shanghai JMT-Bio Inc.
Treatments:
Denosumab